The fourth-quarter earnings season is drawing to a close with results from 411 S&P 500 members or 82.2% of the index's total membership already out, as of Feb 22, 2017.
While Alexion (ALXN) reported a mixed quarter, Celgene provided promising data on a pipeline candidate.
We advise investors to consider biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.
Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.
Alexion Pharmaceuticals, Inc.'s (ALXN) fourth-quarter 2016 earnings (including stock-based compensation expense) of $1.10 cents per share compared with the year ago earnings of 78 cents.
Alexion missed on earnings expectations in the fourth quarter of 2016.
--Global Soliris(R) Revenue Growth Driven by Steady Number of New Patients with PNH and aHUS
Arista Networks ( ANET ): Arista Networks roared through 2016 only to hit a massive snag at the start of the new year. In late January, the CBP revoked an earlier court ruling over an ongoing patent infringement...
The Q4 earnings season is on its last legs as results from 358 S&P 500 members or 71.6% of the index's total membership is already out.
Alexion Pharmaceuticals, Inc. (ALXN) is scheduled to report fourth-quarter 2016 results on Feb 16, before the opening bell.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2016 on Thursday, February...
The Zacks Analyst Blog Highlights: ExxonMobil, Procter & Gamble, Micron, Macy's and Alexion Pharmaceuticals
Research Reports on Exxon, P&G and the Q4 Earnings Season
Biotechnology shares have welcomed this year in style, marking a striking reversal from last year???s dismal performance
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company") (NASDAQ:ALXN)...
Drug stocks were hit once again with President-elect Donald Trump's comments about the sector at his first news conference since his election in November.
NEW YORK, NY / ACCESSWIRE / January 11, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Alexion Pharmaceuticals, Inc. ("Alexion" or the "Company")...
Alexion (ALXN) has filed regulatory applications in both the U.S. and EU for Soliris for the treatment of patients with refractory generalized myasthenia gravis.
Upcoming AWS Coverage on Jazz Pharmaceuticals
Alexion (ALXN) announced that the FDA has granted orphan drug designation to ALXN1210 for the treatment of patients with paroxysmal nocturnal hemoglobinuria.